Heliogen, Inc. Announces Fourth Quarter and Full Year 2024 Financial and Operational Results
Financial and Operational Highlights
-
Continued to prioritize the deployment of our commercially-proven power solutions by taking actions to conserve cash and re-allocate resources from activities that were no longer directly contributing to this goal. Actions taken since
September 30, 2024 included:-
Together with
Woodside Energy (USA) Inc. (“Woodside”), decided not to pursue construction of a concentrated solar energy facility that was designed to demonstrate at commercial scale our next-generation thermal storage technology, to be built inMojave, California (the “Capella Project”). For clarity, Heliogen’s current commercial offering leverages the technologically-proven and commercially mature form of thermal energy storage technology, which has been deployed in existing global concentrated solar power facilities. -
Concluded the targeted plan implemented in
May 2024 , which included a workforce reduction, closing of theLong Beach manufacturing facility (the “Manufacturing Facility”) and a reduction in third-party costs. -
Closed Heliogen’s research and development facility in
Lancaster, California (the “R&D Facility”), which in 2024 had successfully served its purpose of demonstrating Heliogen’s proprietary software could operate in conditions simulating a commercial operating environment. -
Halted construction of Heliogen’s steam plant in west
Texas (the “Texas Steam Plant”).
-
Together with
- Achieved reductions in total selling, general and administrative (“SG&A”) and research and development (“R&D”) expenses for Q4 2024 by 20% sequentially, compared to Q3 2024; and for full year 2024, reductions by 25% compared to full year 2023.
-
Ended the year with liquidity of
$36.9 million . - With guidance from our Board of Directors, continued to explore and evaluate strategic transactions with our third-party financial advisor.
“Reflecting on the past year, I am proud of the
Fourth Quarter and Full Year 2024 Financial Results
During the year ended
In the fourth quarter of 2024,
For the fourth quarter of 2024,
Total SG&A and R&D expenses were
Impairment and other charges were
In connection with the targeted plan,
Net income was
Heliogen’s Adjusted EBITDA was
As of
About
Non-GAAP Financial Information
Management uses certain financial measures, including EBITDA and Adjusted EBITDA, to evaluate our financial and operating performance that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in
EBITDA represents consolidated net income (loss) before (i) interest income, (ii) income tax expense (benefit) and (iii) depreciation and amortization expense. We define Adjusted EBITDA as EBITDA adjusted for certain significant non-cash items and items that management believes are not attributable to or indicative of our on-going operations or that may obscure our underlying results and trends. Please see the accompanying tables for a reconciliation of net loss to EBITDA and Adjusted EBITDA.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical in nature, including the words “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our technology, expectations around our ability to deliver cost-effective, reliable, low-carbon solutions to support a practical energy transition for customers with energy-intensive operations, the outcome of our steps taken to align our operating structure for commercialization with a technology-centric business model, and our ability to continue to explore and evaluate strategic transactions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to fund our future cash obligations and continue as a going concern, (ii) our ability to access sources of capital to finance operations, growth and future capital requirements; (iii) our ability to explore and execute on strategic transactions; (iv) our financial and business performance, including risk of uncertainty in our financial projections and business metrics and any underlying assumptions thereunder; (v) ability to implement changes to our business strategy and future operations; (vi) changes in our financial position, estimated revenues and losses, projected costs, prospects and plans; (vii) our ability to execute our business model, including market acceptance of our planned products and services; (viii) our ability to maintain and enhance our products and brand, and to attract and retain customers; (ix) our ability to scale in a cost-effective manner; (x) changes in applicable laws or regulations; (xi) developments and projections relating to our competitors and industry; and (xii) our ability to protect and commercialize our intellectual property. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the “Risk Factors” section in Part I, Item 1A in our Annual Report on Form 10-K to be filed for the year ended
Condensed Consolidated Statements of Operations ($ in thousands, except per share and share data) (unaudited) |
||||||||||||||||||||
|
|
|
|
|
||||||||||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||||||
|
|
|
|
|
|
|
||||||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenue |
$ |
18,385 |
|
|
$ |
(1,159 |
) |
|
$ |
1,050 |
|
|
$ |
23,224 |
|
|
$ |
4,445 |
|
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
|||||||||||
Cost of services revenue (including depreciation) |
|
804 |
|
|
|
456 |
|
|
|
494 |
|
|
|
4,655 |
|
|
|
3,677 |
|
|
Cost of grant revenue |
|
715 |
|
|
|
827 |
|
|
|
616 |
|
|
|
3,380 |
|
|
|
3,517 |
|
|
Contract loss (adjustments) provisions |
|
(74,117 |
) |
|
|
53,002 |
|
|
|
— |
|
|
|
(74,117 |
) |
|
|
52,854 |
|
|
Total cost of revenue |
|
(72,598 |
) |
|
|
54,285 |
|
|
|
1,110 |
|
|
|
(66,082 |
) |
|
|
60,048 |
|
|
Gross profit (loss) |
|
90,983 |
|
|
|
(55,444 |
) |
|
|
(60 |
) |
|
|
89,306 |
|
|
|
(55,603 |
) |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|||||||||||
Selling, general and administrative |
|
6,606 |
|
|
|
13,268 |
|
|
|
7,854 |
|
|
|
36,320 |
|
|
|
49,495 |
|
|
Research and development |
|
3,284 |
|
|
|
5,660 |
|
|
|
4,509 |
|
|
|
16,335 |
|
|
|
21,028 |
|
|
Impairment and other charges |
|
2,662 |
|
|
|
7,339 |
|
|
|
202 |
|
|
|
7,024 |
|
|
|
8,934 |
|
|
Total operating expenses |
|
12,552 |
|
|
|
26,267 |
|
|
|
12,565 |
|
|
|
59,679 |
|
|
|
79,457 |
|
|
Operating income (loss) |
|
78,431 |
|
|
|
(81,711 |
) |
|
|
(12,625 |
) |
|
|
29,627 |
|
|
|
(135,060 |
) |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Interest income |
|
406 |
|
|
|
560 |
|
|
|
535 |
|
|
|
2,299 |
|
|
|
1,448 |
|
|
Gain (loss) on warrant remeasurement |
|
(8 |
) |
|
|
216 |
|
|
|
53 |
|
|
|
66 |
|
|
|
542 |
|
|
Other income, net |
|
41 |
|
|
|
2,132 |
|
|
|
223 |
|
|
|
561 |
|
|
|
3,473 |
|
|
Net income (loss) before taxes |
|
78,870 |
|
|
|
(78,803 |
) |
|
|
(11,814 |
) |
|
|
32,553 |
|
|
|
(129,597 |
) |
|
Benefit (provision) for income taxes |
|
(1 |
) |
|
|
2 |
|
|
|
(1 |
) |
|
|
(6 |
) |
|
|
(1 |
) |
|
Net income (loss) |
$ |
78,869 |
|
|
$ |
(78,801 |
) |
|
$ |
(11,815 |
) |
|
$ |
32,547 |
|
|
$ |
(129,598 |
) |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|||||||||||
Basic |
$ |
12.86 |
|
|
$ |
(13.15 |
) |
|
$ |
(1.94 |
) |
|
$ |
5.36 |
|
|
$ |
(22.26 |
) |
|
Diluted |
$ |
12.55 |
|
|
$ |
(13.15 |
) |
|
$ |
(1.94 |
) |
|
$ |
5.22 |
|
|
$ |
(22.26 |
) |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Weighted-average number of shares outstanding: |
|
|
|
|
|
|
||||||||||||||
Basic |
|
6,132,588 |
|
|
|
5,991,628 |
|
|
|
6,086,382 |
|
|
|
6,071,530 |
|
|
|
5,822,389 |
|
|
Diluted |
|
6,282,625 |
|
|
|
5,991,628 |
|
|
|
6,086,382 |
|
|
|
6,231,240 |
|
|
|
5,822,389 |
|
Condensed Consolidated Balance Sheets ($ in thousands) (unaudited) |
||||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
2024 |
|
|
|
2023 |
|
ASSETS |
|
|
|
|||||
Cash and cash equivalents |
$ |
36,949 |
|
$ |
62,715 |
|
||
Investments |
|
— |
|
|
12,386 |
|
||
Other current assets |
|
2,129 |
|
|
8,365 |
|
||
Total current assets |
|
39,078 |
|
|
83,466 |
|
||
Non-current assets |
|
5,212 |
|
|
23,567 |
|
||
Total assets |
$ |
44,290 |
|
$ |
107,033 |
|
||
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
|
|||||
Trade payables |
$ |
1,450 |
|
$ |
746 |
|
||
Accrued expenses and other current liabilities |
|
11,164 |
|
|
8,907 |
|
||
Contract liabilities |
|
— |
|
|
17,008 |
|
||
Contract loss provisions |
|
— |
|
|
75,340 |
|
||
Total current liabilities |
|
12,614 |
|
|
102,001 |
|
||
Long-term liabilities |
|
2,658 |
|
|
13,047 |
|
||
Total liabilities |
|
15,272 |
|
|
115,048 |
|
||
Stockholders’ equity (deficit) |
|
29,018 |
|
|
(8,015 |
) |
||
Total liabilities and stockholders’ equity (deficit) |
$ |
44,290 |
|
$ |
107,033 |
|
Reconciliation of Net Income (Loss) to EBITDA and Adjusted EBITDA ($ in thousands) (unaudited) |
||||||||||||||||||||
|
|
|
|
|
||||||||||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||||||
|
|
|
|
|
|
|
||||||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2024 |
|
|
|
2023 |
|
Net income (loss) |
$ |
78,869 |
|
|
$ |
(78,801 |
) |
|
$ |
(11,815 |
) |
|
$ |
32,547 |
|
|
$ |
(129,598 |
) |
|
Interest income |
|
(406 |
) |
|
|
(560 |
) |
|
|
(535 |
) |
|
|
(2,299 |
) |
|
|
(1,448 |
) |
|
Provision (benefit) for income taxes |
|
1 |
|
|
|
(2 |
) |
|
|
1 |
|
|
|
6 |
|
|
|
1 |
|
|
Depreciation and amortization |
|
63 |
|
|
|
450 |
|
|
|
107 |
|
|
|
965 |
|
|
|
2,142 |
|
|
EBITDA |
$ |
78,527 |
|
|
$ |
(78,913 |
) |
|
$ |
(12,242 |
) |
|
$ |
31,219 |
|
|
$ |
(128,903 |
) |
|
Non-reoccurring revenue from contract modification (1) |
|
(17,502 |
) |
|
|
— |
|
|
|
— |
|
|
|
(17,502 |
) |
|
|
— |
|
|
Contract loss (adjustments) provisions (2) |
|
(74,117 |
) |
|
|
53,002 |
|
|
|
— |
|
|
|
(74,117 |
) |
|
|
52,854 |
|
|
Contract losses incurred (3) |
|
(154 |
) |
|
|
(4,338 |
) |
|
|
(492 |
) |
|
|
(1,223 |
) |
|
|
(5,966 |
) |
|
Impairment charges (4) |
|
1,352 |
|
|
|
6,766 |
|
|
|
— |
|
|
|
4,706 |
|
|
|
7,774 |
|
|
Manufacturing Facility closing costs (5) |
|
139 |
|
|
|
— |
|
|
|
— |
|
|
|
300 |
|
|
|
— |
|
|
Severance costs (6) |
|
1,171 |
|
|
|
573 |
|
|
|
202 |
|
|
|
2,018 |
|
|
|
1,160 |
|
|
Share-based compensation (7) |
|
(43 |
) |
|
|
914 |
|
|
|
709 |
|
|
|
2,633 |
|
|
|
(5,164 |
) |
|
(Gain) loss on warrant remeasurement (8) |
|
8 |
|
|
|
(216 |
) |
|
|
(53 |
) |
|
|
(66 |
) |
|
|
(542 |
) |
|
Change in fair value of contingent consideration (9) |
|
— |
|
|
|
(1,642 |
) |
|
|
— |
|
|
|
— |
|
|
|
(353 |
) |
|
Employee retention credit (10) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(41 |
) |
|
Adjusted EBITDA |
$ |
(10,619 |
) |
|
$ |
(23,854 |
) |
|
$ |
(11,876 |
) |
|
$ |
(52,032 |
) |
|
$ |
(79,181 |
) |
________________ |
||
(1) |
|
Represents a favorable cumulative adjustment to project revenue, which primarily consisted of deferred revenue, resulting from the cancellation of the |
(2) |
|
Represents contract loss (adjustments) provisions with customers for which estimated costs to satisfy performance obligations exceeded considerations expected to be realized. During the year ended |
(3) |
|
The contract loss (adjustment) provision is reduced and recognized in cost of revenue as expenditures are incurred during the periods based on percentages of completion and related revenue is recognized. |
(4) |
|
Impairment charges during the year ended |
(5) |
|
Represents costs associated with closing the Manufacturing Facility |
(6) |
|
Represents severance costs related to employee severance and related benefits. |
(7) |
|
Share-based compensation for the year ended |
(8) |
|
Represents the change in fair value on our outstanding warrant liabilities. |
(9) |
|
Represents the change in fair value of our contingent consideration associated with the acquisition of |
(10) |
|
Represents an adjustment to the employee tax credit pursuant to the Coronavirus Aid, Relief and Economic Security Act (CARES Act) recorded as grant revenue. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327359821/en/
Heliogen Investors Contact:
Chief Financial Officer
Phelps.Morris@heliogen.com
Heliogen Media Contact:
HeliogenPR@icrinc.com
Source: